## Characteristics and outcomes of COVID-19 patients during

## B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in

## **89** German hospitals

Johannes Leiner<sup>1,2</sup>, MD; Vincent Pellissier<sup>1</sup>, PhD; Sven Hohenstein<sup>1</sup>, PhD;

Sebastian König<sup>1,2</sup>, MD; Ekkehard Schuler<sup>3</sup>, MD; Robert Möller<sup>3</sup>, MD; Irit Nachtigall<sup>3</sup>, MD;

Marzia Bonsignore<sup>4,5</sup>, MD; Gerhard Hindricks<sup>1,2</sup>, MD; Ralf Kuhlen<sup>6</sup>, MD, PhD

and Andreas Bollmann<sup>1,2</sup>, MD, PhD

## Affiliations

<sup>1</sup>Leipzig Heart Institute, Leipzig, Germany

<sup>2</sup>Heart Center Leipzig at University of Leipzig, Department of Electrophysiology, Leipzig,

Germany

<sup>3</sup>Helios Hospitals GmbH, Berlin, Germany

<sup>4</sup>Helios St. Anna Hospital, Department of Infectiology and Hospital Hygiene, Duisburg,

Germany

<sup>5</sup>Institute for Medical Laboratory Diagnostics, Center for Clinical and Translational Research, Helios University Hospital Wuppertal, University of Witten/Herdecke, Wuppertal, Germany

<sup>6</sup>Helios Health GmbH, Berlin, Germany

## **Corresponding author**

Johannes Leiner, MD Heart Center Leipzig at University of Leipzig, Department of Electrophysiology Russenstrasse 69A, 04289 Leipzig, Germany E-Mail: johannes.leiner@helios-gesundheit.de Phone: +49 341 865 251573

Word count: 2,506 (Main text); 298 (Abstract)

#### Abstract

**Background:** The SARS-CoV-2 variant of concern B.1.1.529 (Omicron) was first described in November 2021 and soon became the dominant variant worldwide. Existing data suggests a reduced disease severity in comparison to B.1.617.2 (Delta). Differences in characteristics and in-hospital outcomes of patients with COVID-19 in Germany during the Omicron period compared to Delta are not thoroughly studied. Surveillance for severe acute respiratory infections (SARI) represents an integral part of infectious disease control in Germany.

Methods: Administrative data from 89 German Helios hospitals was retrospectively analysed. Laboratory-confirmed SARS-CoV-2 infections were identified by ICD-10-code U07.1 and SARI cases by ICD-10-codes J09-J22. COVID-19 cases were stratified by concomitant SARI. A nine-week observational period between December 6, 2021 and February 6, 2022 was defined and divided into three phases with respect to the dominating virus variant (Delta, Delta to Omicron transition, Omicron). Regression analyses adjusted for age, gender and Elixhauser comorbidities were applied to assess in-hospital patient outcomes. **Results:** A total cohort of 4.494 inpatients was analysed. Patients in the Omicron dominance period were younger (mean age 61.6 vs. 47.8; p<0.01), more likely to be female (54.7% vs. 47.5%; p<0.01) and characterized by a lower comorbidity burden (mean Elixhauser comorbidity index 8.2 vs. 5.4; p<0.01). Comparing Delta and Omicron periods, patients were at significantly lower risk for intensive care treatment (adjusted odds ratio 0.64 [0.51-0.8]; p<0.001), mechanical ventilation (adjusted odds ratio 0.38 [0.28-0.51]; p<0.001), and inhospital mortality (adjusted odds ratio 0.42 [0.32-0.56]; p<0.001). This also applied to the separate COVID-SARI group. During the Delta to Omicron transition, case numbers of COVID-19 without SARI exceeded COVID-SARI.

**Conclusion:** Patient characteristics and outcomes differ during the Omicron dominance period as compared to Delta suggesting a reduced disease severity with Omicron infections. SARI surveillance might play a crucial role in assessing disease severity of future SARS-CoV-2 variants.

# Abbreviations

CI	Confidence interval
COVID-19	Coronavirus disease 2019
ECDC	European Centre for Disease Prevention and Control
GLMM	Generalized linear mixed models
ICD-10-GM	International Statistical Classification of Diseases and Related Health Problems Version 10,
	German Modification
ICU	Intensive care unit
LMM	Linear mixed models
OPS	Operation and Procedure Classification System
RKI	Robert-Koch-Institute
SARI	Severe acute respiratory infection
SARI+	COVID-19 with SARI
SARI-	COVID-19 without SARI
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
VoC	Variant of Concern
WHO	World Health Organization

## Introduction

Various variants of SARS-CoV-2 continue to emerge during the COVID-19 pandemic. The European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) currently list several virus lineages under close monitoring including the circulating variants of concern (VoC) B.1.617.2 (Delta) and B.1.1.529 (Omicron) <sup>1 2</sup>. First described in South Africa and reported to the WHO on November 24, 2021 <sup>3</sup>, Omicron has become the predominant SARS-CoV-2 variant worldwide throughout the past two months, with a share of sequences in European countries of almost 100% <sup>4</sup>. Several sub-lineages of Omicron exist with BA.1 and BA.2 being the most common ones <sup>5</sup>. Numbers of BA.2 increased rapidly worldwide as of January 2022 <sup>6</sup> with a proportion of up to 72% among Omicron sequences recently reported for Germany by the federal government agency Robert-Koch-Institute (RKI)<sup>7</sup>.

Although Omicron carries several previously observed mutations, its genome markedly differs from those of other VoC which leads to significant differences in viral behaviour in comparison to Delta with respect to transmissibility and immune evasion <sup>8-10</sup>. However, early data from South Africa suggested a reduced disease severity in adults with Omicron infections <sup>11</sup>. In accordance therewith, reduced odds for hospitalisation or death were reported for patient cohorts in Norway <sup>12</sup> Canada <sup>13</sup> and the US <sup>14</sup>. Most recently, Nyberg *et al.* presented data of over 1.5 million laboratory-confirmed COVID-19 cases in the United Kingdom and found a substantially decreased risk for hard outcomes like hospital admission or death in patients infected with Omicron as compared to Delta <sup>15</sup>. The findings were consistent even when only unvaccinated individuals were analysed suggesting a "real" reduction in viral pathogenicity.

So far, outcome data of hospitalized patients in Germany infected during the Omicron dominance period is scarce. Weekly reports with descriptive data on incidence, hospitalizations and mortality are presented by the RKI <sup>16</sup>, however, structured statistical analyses are lacking. The aim of this study was to evaluate characteristics and outcomes of hospitalized patients with COVID-19 in Germany, estimate the disease severity of Omicron and investigate temporal trends during the Delta to Omicron transition phase. To serve this purpose, we assessed the frequency of severe acute respiratory infections (SARI) in COVID-19 patients.

#### Methods

We conducted a retrospective claims data-based analysis of inpatients treated in 89 German Helios hospitals with laboratory confirmed SARS-CoV-2 infection. ICD-10-GM-code U07.1 (International Statistical Classification of Diseases and Related Health Problems Version 10, German Modification) as main or secondary diagnosis was used to identify COVID-19. Present SARS-CoV-2 infection was linked to the occurrence of SARI, commonly defined by the WHO as an acute respiratory illness with a history of fever, cough, onset within the past 10 days and requiring hospitalization <sup>17</sup>. SARI cases were identified by ICD-10-codes J09-J22 (main or secondary diagnosis) in accordance with common methods of SARI surveillance <sup>18</sup>. ICD-10-codes J09-J22 comprise influenza and pneumonia (J09-J18), acute bronchitis (J20), acute bronchiolitis (J21) and unspecified acute lower respiratory tract infection (J22). To evaluate of temporal trends of SARI and COVID-19, we analysed the whole pandemic period from March 2020 to February 2022. Patients with full inpatient treatment during the observational period of nine weeks between December 6, 2021 and February 6, 2022 underwent a detailed analysis. Relevant treatments and patient characteristics were analysed according to the Operation and Procedure Classification System (OPS) and ICD-10-codes based on the Elixhauser comorbidity index <sup>19</sup> (Supplemental Table 1). The following outcomes and treatments were analysed: intensive care treatment (OPS-codes 8-980, 8-98f or duration of intensive-care stay > 0), mechanical ventilation (OPS-codes 8-70x, 8-71x or duration of ventilation > 0), in-hospital mortality, length of stay (in days), length of stay at intensive care unit (ICU, in days), duration of mechanical ventilation (hours). For the analysis of in-hospital mortality, we excluded cases with discharge due to hospital transfer or unspecified reasons.

Based on data made available by the RKI <sup>20</sup> but assuming a one week delay between infection and consecutive hospital admission, three cohorts and time periods were defined with respect to the dominating virus variant: Delta dominance (2021-12-06 to 2021-12-26), Delta to Omicron transition phase (2021-12-27 to 2022-01-16) and Omicron dominance (2022-01-17 to 2022-02-06).

Inferential statistics were based on generalized linear mixed models (GLMM) specifying hospitals as random factor <sup>21</sup>. We employed logistic GLMMs function for dichotomous data and linear mixed models (LMM) for continuous data. Effects were estimated with the lme4 package (version 1.1-26) <sup>22</sup> in the R environment for statistical computing (version 4.0.2, 64-bit build) <sup>23</sup>. For all tests we apply a two-tailed 5% error criterion for significance. For the description of the patient characteristics of the cohorts, we employed  $\chi^2$ -tests for binary variables and analysis of variance for numeric variables. We report proportions, means, standard deviations, and p-values.

For the comparison of proportions of symptoms as well as selected treatments and outcomes in the different cohorts, we used logistic GLMMs with logit link function. We report proportions, odds ratios together with confidence intervals and p-values. The analysis of the outcome variables length of stay, length of ICU stay, and duration of mechanical ventilation was performed via LMMs. For these analyses, we log-transformed the dependent variables. We report means, standard deviations, medians, interquartile ranges, and p-values. The computation of p-values is based on the Satterthwaite approximation for degrees of freedom.

GLMMs and LMMs were fitted adjusting for age, gender and Elixhauser score. Age and gender are normalized before fitting the models. We report statistics for Elixhauser comorbidity index as well as its items. For the weighted Elixhauser comorbidity index, the Agency for Healthcare Research and Quality (AHRQ) algorithm was applied <sup>19</sup>.

The analysis was carried out according to the principles outlined in the Declaration of Helsinki. Patient-related data were stored in an anonymized form. The local ethics committee (vote: AZ490/20-ek) and the Helios Kliniken GmbH data protection authority approved data use for this study.

#### **Results**

The central illustration displays trends in COVID-19 diagnoses since the onset of the global pandemic stratified by additionally encoded SARI. During each of the first four pandemic waves, a large proportion of inpatients with COVID-19 also had SARI (hereafter referred to as SARI+). The share of patients with present SARS-CoV-2 infection but without SARI (hereafter referred to as SARI-) mostly followed the course of the pandemic waves but case numbers remained significantly below those with SARI. During the Delta to Omicron transition phase, this relation changed. Case numbers of SARI- exceeded SARI+ for the first time in the pandemic (Figure 1, Delta to Omicron transition phase marked in green).

A total of 4,494 patients with inpatient treatment and laboratory confirmed COVID-19 diagnosis were identified in the period 2021-12-06 to 2022-02-06 (Table 1). Patient characteristics are shown in Supplemental Table 2. Proportion of SARI+ cases decreased from 64.3% in the Delta dominance period to 30.6% in the Omicron dominance period (p<0.01). Mean age [SD] in the total COVID-19 cohort decreased from 61.6 [22.2] to 47.8 [28.1] (p<0.01). This was driven by a significant increase of patients in the age group  $\leq$ 59 years. Patients in the SARI+ cohort were older as compared to SARI- and mean age also

decreased significantly throughout the observational period when the separate cohorts were analysed (Supplemental Table 2). Proportion of male patients decreased significantly for the total cohort (52.5% to 45.3%; p<0.01). Regarding comorbidities, a significant reduction in the mean weighted Elixhauser comorbidity index could be observed for the total cohort with 8.2 [9.4] during Delta and 5.4 [8.7] during Omicron (p<0.01) and the SARI- cohort (6.1 [8.9] to 4.1 [7.8]; p<0.01) but not for SARI+ (9.4 [9.5] to 8.5 [9.8]; p=0.22).

For all treatments and outcomes, odds were significantly reduced comparing the Delta and Omicron periods in the total COVID-19 cohort (Table 2). Adjusted odds ratios [95%CI] were 0.64 [0.51-0.80] for intensive care treatment (p<0.001), 0.38 [0.28-0.51] for mechanical ventilation (p<0.001) and 0.42 [0.32-0.56] for in-hospital mortality (p<0.001). Raw inhospital mortality rates were 16.3% for the Delta period, 12.2% for Delta to Omicron transition phase and 5.5% for the Omicron period. Considering the SARI+ cohort, a similar picture emerged with adjusted odds ratios comparing Delta and Omicron of 0.61 [0.45-0.83] for intensive care treatment (p=0.002), 0.55 [0.39-0.77] for mechanical ventilation (p<0.001) and 0.63 [0.46-0.88] for in-hospital mortality (p=0.006). No significant risk reduction could be observed in the SARI- cohort for intensive care treatment and mechanical ventilation but for in-hospital mortality (p=0.021). Length of stay, length of ICU stay as well as the duration of mechanical ventilation were reduced significantly in the total cohort comparing Delta and Omicron (Table 3), regarding length of stay and duration of mechanical ventilation also in the SARI+ cohort.

#### Discussion

We present an analysis of 4,494 inpatients treated in 89 German hospitals with laboratory confirmed SARS-CoV-2 infection during the transition period of dominating virus variants Delta and Omicron. To the best of our knowledge, this is the first study comparing patient

outcomes of COVID-19 during the fourth and fifth pandemic wave in Germany with respect to the dominating VoC.

Our analysis yielded the following findings: Occurrence of SARI is common among COVID-19 patients which was most obvious during the first four pandemic waves. During the Delta to Omicron transition phase, case numbers of SARI- patients exceeded those of SARI+. We noticed a significant change in patient characteristics. In the phase of Omicron dominance, patients were younger, more likely to be female and characterized by a lower comorbidity burden. Patients infected during the Omicron dominance period compared to Delta were less likely to receive intensive care treatment, mechanical ventilation and were at significantly lower mortality risk in the total cohort as well as the SARI+ cohort. This leads to the assumption that disease severity in Omicron might be lower. Concomitant occurrence of SARI in hospitalized patients seems to correlate with the severity of SARS-CoV-2 infections. SARI surveillance could therefore play a crucial role in pandemic monitoring. However, future studies are needed to confirm this observation.

Our results are in line with the findings by Nyberg *et al.* <sup>15</sup> and other previously mentioned studies <sup>12-14</sup> as to the dominant SARS-CoV-2 variant Omicron appears to cause milder courses of infection. Importantly, Nyberg *et al.* performed stratifications by vaccination status and history of past infection which confirmed the reduction of disease severity even in unvaccinated subjects. As administrative data does not contain information about vaccination status, a similar stratification could not be executed within our analysis. Therefore, potential influence of an underlying population immunity which prevents severe courses of infection cannot be ruled out. The current pandemic situation in Hong Kong shows that Omicron can indeed lead to high case fatality rates in a rather non-immunized population due to low vaccination rates and low background immunity because of the so-called "Zero-COVID strategy" <sup>24</sup>. The effect of booster vaccinations, which offer 70% protection against hospitalisation and death as was reported Nyberg *et al.*<sup>15</sup>, must also be highlighted as a large

proportion of booster doses were administered during the Omicron period <sup>14</sup>. However, our observation that patients in the SARI+ group had a comparable comorbidity burden during Omicron and Delta phases (as indicated by Elixhauser comorbidity index values) but still were at lower risk for adverse outcomes strengthens the assumption of a reduced disease severity which is also backed by a recent experimental study available as a preprint <sup>25</sup>.

According to our data, Omicron affects a younger population, more frequently females and patients with lower comorbidity burden. A similar shift in patient characteristics was observed in previous studies investigating the clinical differences of Omicron and Delta – for example in a recent study by Bouzid *et al.* who analysed 1,716 patients presenting to 13 emergency departments in France <sup>26</sup>. In this analysis, prevalence of comorbidities (except obesity) did not differ between the groups, however, only a few distinct comorbidities were surveyed. With respect to outcomes, the findings were comparable to our analysis with reduced risk among Omicron patients for ICU treatment, mechanical ventilation and inhospital death <sup>26</sup>. A possible explanation for the shift in demographic parameters, especially age, might be the proportion of booster vaccinations among people aged 60+ which is significantly higher in comparison to people in the age group 18-59 according to RKI data <sup>27</sup>.

Leveraging existing national and international surveillance systems to monitor pandemic trends is of crucial importance as was also stated by the WHO and ECDC <sup>28-31</sup>. In Germany, an ICD-code-based SARI surveillance system (ICOSARI) closely linked to the RKI was introduced in 2017 <sup>18</sup>. In a recent preprint article, Tolksdorf *et al.* analysed hospitalization numbers and ICU treatments derived from ICOSARI in the first three pandemic waves, compared those with the German national notification system for SARS-CoV-2 infections and found a more accurate estimation of hospitalizations and ICU treatments utilizing ICOSARI data <sup>30</sup>. Monitoring trends of SARI-COVID cases has yet become an integral part of pandemic surveillance in Germany <sup>16</sup>. Our study further highlights,

that this easily applicable system fully based on administrative data could play a central role in assessing disease severity.

## Limitations

We acknowledge several limitations in connection with this study. First, some limitations must be attributed to administrative data in general as data quality depends on correct coding and data is stored for remuneration reasons. However, SARI surveillance in Germany utilizing claims data is a robust and valid approach as was mentioned previously <sup>18</sup>. Second, laboratory- confirmed COVID-19 cases were identified through ICD-10-codes and no data for viral genome sequencing was available which could have potentially biased the results. Thus, identification of Omicron and Delta cases were based on epidemiological data provided by the RKI <sup>16 32</sup>. In addition, differentiation between BA.1 and BA.2 sub-lineages was not possible. Third, as outlined above, the effect of person-level vaccination status could not be assessed in this study as respective data was not available. Fourth, identification of COVID-19 cases is dependent on correct testing and cases might stay undetected. However, in Helios hospitals, reverse transcriptase polymerase chain reaction (RT-PCR) testing is mandatory for inpatients in addition to rapid antigen tests. Fifth, nosocomial COVID-19 cases were not excluded in the present analysis. The increased transmissibility of Omicron could have led to more incident infections with unknown impact on disease severity assessment <sup>14</sup>. Sixth, this analysis included all patients hospitalized within the observational period with a documented COVID-19 diagnosis. The reason for admission was therefore not considered which may have led to possible selection bias as, due to postponement of elective procedures, relatively more patients with severe diseases that require urgent treatment entered the healthcare during the fourth and fifth pandemic wave.

# Conclusion

During the Omicron dominance period, numbers of SARI in hospitalized patients with COVID-19 were lower relative to Non-SARI cases. Analysis of timely trends revealed that this represents a unique finding during the pandemic's course. Adjusted for age, gender and comorbidity burden, the risk for adverse hospital outcomes (ICU treatment, mechanical ventilation, and in-hospital mortality) was substantially decreased during Omicron dominance as compared to Delta. Patients affected by Omicron were younger, more likely to be female and the comorbidity burden was lower. Continuous ICD-code based SARI monitoring could contribute decisively to COVID-19 surveillance and evaluation of disease severity especially in the light of possible future virus variants.

#### Acknowledgements

**Guarantor statement:** Mr. Johannes Leiner (JL) takes full responsibility for the content of the manuscript, including the data and analysis.

**Author contributions:** VP, SH, SK, ES, RM, GH, RK, AB contributed substantially to the study design, data analysis and interpretation and revision of the manuscript and gave final approval for publishing.

**Conflicts of interest:** We declare no conflicts of interest associated with this publication. **Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## **Statement of Ethics**

The analysis was carried out according to the principles outlined in the Declaration of Helsinki. Patient-related data were stored in a pseudonymized form. The local ethics committee (vote: AZ490/20-ek) and the Helios Kliniken GmbH data protection authority approved data use for this study.

#### **Data Availability Statement**

The data that support the findings of this study are not publicly available as they contain information that could compromise the privacy of research participants but are available from the corresponding author, Mr. Johannes Leiner (Johannes.leiner@helios-gesundheit.de) upon reasonable request.

## References

- 1. European Centre for Disease Prevention and Control (ECDC): SARS-CoV-2 variants of concern as of 11 March 2022 [Available from: <u>https://www.ecdc.europa.eu/en/covid-19/variants-concern</u> accessed March 18, 2022.
- 2. World Health Organization (WHO): Tracking SARS-CoV-2 variants [Available from: <a href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</a> accessed March 18, 2022.
- 3. World Health Organization (WHO): Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Available from: <u>https://www.who.int/news/item/26-11-2021-</u> <u>classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern</u> accessed March 18, 2022.
- 4. Our World in Data: Share of SARS-CoV-2 sequences that are the omicron
- variant as of Mar 17, 2022 [Available from: <u>https://ourworldindata.org/grapher/covid-cases-omicron?region=Europe&country=GBR~FRA~BEL~DEU~ITA~ESP~USA~ZAF~B</u> <u>WA~AUS</u> accessed March 18, 2022.
- World Health Organization (WHO) Statement on Omicron sublineage BA.2 [Available from: <u>https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineageba.2</u> accessed March 28, 2022.

6. WHO (World Health Organization): Enhancing response to Omicron SARS-CoV-2 variant:

- Technical brief and priority actions for Member States [Available from: <u>https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-</u> (b.1.1.529)-technical-brief-and-priority-actions-for-member-states accessed March 28, 2022.
- 7. Robert-Koch-Institut (RKI): Wöchentlicher Lagebericht des RKI
- zur Coronavirus-Krankheit-2019
- (COVID-19) vom 24.03.2022 [Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Situationsberichte/ Wochenbericht/Wochenbericht\_2022-03-24.pdf? blob=publicationFile accessed March 28, 2022.
- Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *The Lancet* 2021;398(10317):2126-28. doi: 10.1016/s0140-6736(21)02758-6
- Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS□CoV□2 Omicron variant. *Journal of Medical Virology* 2022 doi: 10.1002/jmv.27643
- Jung C, Kmiec D, Koepke L, et al. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? *Journal of Virology*;96(6):e02077-21. doi: 10.1128/jvi.02077-21
- Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet* 2022;399(10323):437-46. doi: 10.1016/s0140-6736(22)00017-4
- Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. *Eurosurveillance* 2022;27(4) doi: 10.2807/1560-7917.es.2022.27.4.2200077
- 13. Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. *JAMA* 2022 doi: 10.1001/jama.2022.2274
- 14. Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-

> CoV-2 High Transmission Periods — United States, December 2020–January 2022. *MMWR Morbidity and Mortality Weekly Report* 2022;71(4):146-52. doi: 10.15585/mmwr.mm7104e4

- Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet* 2022 doi: 10.1016/s0140-6736(22)00462-7
- 16. Robert-Koch-Institut (RKI): Wochenberichte zu COVID-19 [Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Situationsberichte/ Wochenbericht/Wochenberichte\_Tab.html;jsessionid=8286D2EA87630E86B19A3F1 014BD10C8.internet051?nn=13490888 accessed March 29, 2022.
- Fitzner J, Qasmieh S, Mounts AW, et al. Revision of clinical case definitions: influenzalike illness and severe acute respiratory infection. *Bulletin of the World Health Organization* 2018;96(2):122-28. doi: 10.2471/blt.17.194514
- Buda S, Tolksdorf K, Schuler E, et al. Establishing an ICD-10 code based SARIsurveillance in Germany – description of the system and first results from five recent influenza seasons. *BMC Public Health* 2017;17(1) doi: 10.1186/s12889-017-4515-1
- Moore BJ, White S, Washington R, et al. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: The AHRQ Elixhauser Comorbidity Index. *Med Care* 2017;55(7):698-705. doi: 10.1097/MLR.000000000000735 [published Online First: 2017/05/13]
- 20. Robert-Koch-Institut (RKI): Wöchentlicher Lagebericht des RKI
- zur Coronavirus-Krankheit-2019 (COVID-19) vom 24.02.2022 [Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Situationsberichte/ Wochenbericht/Wochenbericht\_2022-02-24.pdf? blob=publicationFile accessed March 22, 2022.
- Baayen RH, Davidson DJ, Bates DM. Mixed-effects modeling with crossed random effects for subjects and items. *Journal of Memory and Language* 2008;59(4):390-412. doi: 10.1016/j.jml.2007.12.005
- 22. Bates D, Mächler M, Bolker B, et al. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software* 2015;67(1):1 - 48. doi: 10.18637/jss.v067.i01
- 23. R Core Team (2022). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
- [Available from: <u>https://www.R-project.org/</u>. accessed March 29, 2022.
- Taylor L. Covid-19: Hong Kong reports world's highest death rate as zero covid strategy fails. *BMJ* 2022:o707. doi: 10.1136/bmj.o707
- 25. Diamond M, Halfmann P, Maemura T, et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters: Research Square Platform LLC, 2021.
- 26. Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments. *Annals of Internal Medicine* 2022 doi: 10.7326/m22-0308
- 27. Robert-Koch-Institut (RKI): Digitales Impfquotenmonitoring zur COVID-19-Impfung [Available from: <u>https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Daten/Impfquoten-Tab.html</u> accessed March 31, 2022.
- 28. European Centre for Disease Prevention and Control (ECDC): Strategies for the surveillance of COVID-19 [Available from: <u>https://www.ecdc.europa.eu/en/publications-data/strategies-surveillance-covid-19</u> accessed March 31, 2022.

- 29. World Health O. Operational considerations for COVID-19 surveillance using GISRS: interim guidance, 26 March 2020. Geneva: World Health Organization, 2020.
- 30. Tolksdorf K, Haas W, Schuler E, et al. Syndromic surveillance for severe acute respiratory infections (SARI) enables valid estimation of COVID-19 hospitalization incidence and reveals underreporting of hospitalizations during pandemic peaks of three COVID-19 waves in Germany, 2020-2021: Cold Spring Harbor Laboratory, 2022.
- 31. Klavs I, Serdt M, Učakar V, et al. Enhanced national surveillance of severe acute respiratory infections (SARI) within COVID-19 surveillance, Slovenia, weeks 13 to 37 2021. *Eurosurveillance* 2021;26(42) doi: 10.2807/1560-7917.es.2021.26.42.2100937
- 32. Robert-Koch-Institut (RKI): Deutscher Elektronischer Sequenzdaten-Hub (DESH) [Available from: <u>https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/DESH/DESH.html</u> accessed March 31, 2022.

## Tables

Table 1: Cohorts and case numbers

Table 2: Comparison of outcomes and treatments, adjusted for age, gender and Elixhauser score.

Table 3: Length of stay, adjusted for age, gender and Elixhauser score.

## **Figures**


Central illustration: COVID-19 cases since beginning of 2020 stratified by encoded SARI.

# **Supplementary Material**

Supplemental Table 1: ICD-10-GM-codes used to calculate Elixhauser comorbidity score

(according to Moore et al., 2017)

Supplemental Table 2: Baseline characteristics



#### Central illustration: COVID-19 cases since beginning of 2020 stratified by encoded SARI.

The coloured bars represent three phases with respect to the dominating SARS-CoV-2 variants. SARI = Severe Acute Respiratory Infection; SARI- = COVID-19 without SARI; SARI+ = COVID-19 with SARI

## Table 1: Cohorts and case numbers

	Nu	mber of case	s	Time periods				
Cohort	Total	SARI-	SARI+	Admission date	Discharge date			
Delta	1,654	590	1,064	2021-12-06	2021-12-26			
Delta to Omicron	1,091	522	569	2021-12-27	2022-01-16			
Omicron	1,749	1,214	535	2022-01-17	2022-02-06			
Whole period	4,494	2,326	2,168	//	//			

SARI = Severe Acute Respiratory Infection

_			, ,	0,00						
		Total			SARI-		SARI+			
Cohort	Proportion (n)	Odds ratio (95% CI)	P value	Proportion (n)	Odds ratio (95% CI)	P value	Proportion ( <i>n</i> )	Odds ratio (95% CI)	<i>P</i> value	
Intensive care treat	tment									
Delta	16.6% (275)			8.3% (49)			21.2% (226)			
Delta to Omicron	16.2% (177)	1.11 (0.89-1.38)	0.372	10.9% (57)	1.56 (1.01-2.40)	0.046	21.1% (120)	1.08 (0.83-1.40)	0.585	
Omicron	9.5% (167)	0.64 (0.51-0.80)	< 0.001	7.2% (88)	1.13 (0.75-1.70)	0.549	14.8% (79)	0.61 (0.45-0.83)	0.002	
Mechanical ventila	tion		11			1		1		
Delta	12.2% (202)			1.0% (6)			18.4% (196)			
Delta to Omicron	10.8% (118)	1.01 (0.79-1.31)	0.914	0.8% (4)	0.83 (0.23-3.00)	0.781	20.0% (114)	1.25 (0.95-1.65)	0.106	
Omicron	4.0% (70)	0.38 (0.28-0.51)	< 0.001	0.9% (11)	1.15 (0.42-3.18)	0.789	11.0% (59)	0.55 (0.39-0.77)	< 0.001	
In-hospital mortali	ty*		11	I		1	I	1		
Delta	16.3% (254)			3.9% (22)			23.4% (232)			
Delta to Omicron	12.2% (126)	0.90 (0.70-1.17)	0.436	2.8% (14)	0.95 (0.46-1.94)	0.888	21.1% (112)	1.02 (0.76-1.36)	0.911	
Omicron	5.5% (94)	0.42 (0.32-0.56)	< 0.001	1.1% (13)	0.43 (0.21-0.88)	0.021	15.7% (81)	0.63 (0.46-0.88)	0.006	

#### Table 2: Comparison of outcomes and treatments, adjusted for age, gender and Elixhauser score.

\*based on 4,286 cases (95.4%). We excluded cases with discharge due to hospital transfer or unspecified reason. CI = Confidence interval; SARI = Severe Acute Respiratory Infection

	Total				SARI-					SARI+			
Cohort	Mean (SD)	Median (IQR)	Coefficient (95% CI)	P value	Mean (SD)	Median (IQR)	Coefficient (95% CI)	P value	Mean (SD)	Median (IQR)	Coefficient (95% CI)	P value	
Length of stay												1	
Delta	$5.5 \pm 3.8$	4.0 [3, 7]			4.1 ±3.3	3.0 [2, 5]			6.3 ±3.8	6.0 [3, 8]			
Delta to Omicron	4.9 ±3.8	4.0 [2, 7]	-0.06 (-0.10 to -0.02)	< 0.01	3.6 ±3.1	3.0 [2, 5]	-0.03 (-0.09 to 0.03)	0.29	6.1 ±4.1	5.0 [3, 8]	-0.03 (-0.08 to 0.03)	0.35	
Omicron	$3.9 \pm 3.1$	3.0 [2, 5]	-0.16 (-0.20 to -0.12)	< 0.01	3.4 ±2.8	2.0 [2, 4]	-0.04 (-0.09 to 0.01)	0.16	5.1 ±3.6	4.0 [2, 7]	-0.16 (-0.21 to -0.10)	< 0.01	
Length of stay at I	CU*											1	
Delta	4.5 ±3.6	3.0 [2, 6]			2.7 ±2.3	2.0 [1, 3]			4.9 ±3.8	4.0 [2, 7]			
Delta to Omicron	4.2 ±3.7	3.0 [1, 6]	-0.11 (-0.27 to 0.05)	0.16	1.8 ±1.3	1.0 [1, 2]	-0.32 (-0.54 to -0.09)	< 0.01	5.3 ±4.0	4.0 [2, 7]	0.09 (-0.09 to 0.27)	0.34	
Omicron	$3.2\pm3.2$	2.0 [1, 4]	-0.39 (-0.55 to -0.23)	< 0.01	1.9 ±1.5	1.0 [1, 2]	-0.26 (-0.47 to -0.05)	0.02	4.5 ±3.9	3.0 [2, 6]	-0.15 (-0.36 to 0.06)	0.17	
Duration of mecha	nical ventilati	ion <sup>†</sup>										1	
Delta	104.7 ±87.9	83.0 [37, 149]			67.7 ±63.5	70.0 [36, 100]			105.4 ±88.3	83.5 [37, 150]			
Delta to Omicron	95.1 ±95.5	58.0 [22, 154]	-0.36 (-0.71 to -0.01)	0.05	23.7 ±18.6	26.0 [15, 34]	-1.76 (-3.93 to 0.41)	0.16	97.5 ±96.1	61.0 [22, 154]	-0.34 (-0.70 to 0.02)	0.06	
Omicron	$78.0 \pm \! 88.3$	41.0 [12, 135]	-0.63 (-1.08 to -0.19)	< 0.01	42.9 ±30.8	36.0 [26, 52]	-0.13 (-1.90 to 1.64)	0.89	83.8 ±93.5	41.5 [10, 154]	-0.63 (-1.11 to -0.16)	< 0.01	

## Table 3: Length of stay, adjusted for age, gender and Elixhauser score.

\* Based on 1,234 cases (13.7%). We excluded cases with length of stay at ICU = 0;.† Based on 598 cases (6.7%). We excluded cases with duration of ventilation = 0; CI = Confidence interval; SARI = Severe Acute Respiratory Infection